Patents by Inventor Laurent Boissel

Laurent Boissel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
    Publication number: 20240010979
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Application
    Filed: July 18, 2023
    Publication date: January 11, 2024
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • Modified NK-92 haNK003 cells for the clinic
    Patent number: 11753625
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: September 12, 2023
    Assignee: ImmunityBio, Inc.
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • GENETICALLY MODIFIED NK-92 CELLS HAVING A SAFETY SWITCH
    Publication number: 20220062343
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: November 18, 2021
    Publication date: March 3, 2022
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
    Patent number: 11207350
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: December 28, 2021
    Assignee: ImmunityBio, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • CHEMOKINE RESPONSIVE ACTIVATED NATURAL KILLER CELLS WITH SECONDARY HOMING ACTIVATION FOR VERIFIED TARGETS
    Publication number: 20210324042
    Abstract: Provided herein are modified NK-92 cells comprising a nucleic acid encoding C—C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C—C motif ligand 21 (CCL21), a nucleic acid encoding C—C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells.
    Type: Application
    Filed: August 1, 2018
    Publication date: October 21, 2021
    Inventors: Nathan SCHOMER, Laurent BOISSEL, Hans KLINGEMANN
  • GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER
    Publication number: 20210236550
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: March 30, 2021
    Publication date: August 5, 2021
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
    Patent number: 11000550
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: May 11, 2021
    Assignee: NANTKWEST, INC.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
    Publication number: 20200347351
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Application
    Filed: July 23, 2020
    Publication date: November 5, 2020
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • Modified NK-92 haNK003 cells for the clinic
    Patent number: 10801013
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: October 13, 2020
    Assignee: NantKwest, Inc.
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBOIDES FOR THE TREATMENT OF CANCER
    Publication number: 20200306312
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Modified NK-92 haNK003 cells for the clinic
    Patent number: 10774310
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: September 15, 2020
    Assignee: NantKwest, Inc.
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
    Patent number: 10736921
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: August 11, 2020
    Assignee: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • METHODS FOR TREATING MERKEL CELL CARCINOMA (MCC) USING NK-92 CELLS
    Publication number: 20200171087
    Abstract: Provided herein are methods of treating merkel cell carcinoma. The methods include selecting a subject having merkel cell carcinoma and administering to the subject a therapeutically effective amount of NK-92 cells, wherein administration treats the merkel cell carcinoma in the subject.
    Type: Application
    Filed: June 19, 2018
    Publication date: June 4, 2020
    Applicant: NANTKWEST, INC.
    Inventors: Hans Klingemann, Tien Lee, Laurent Boissel
  • NK-92 CELLS AND IL-15 AGONIST COMBINATION THERAPY
    Publication number: 20200121720
    Abstract: Provided herein are methods of treating merkel cell carcinoma. The methods include selecting a subject having merkel cell carcinoma and administering to the subject a therapeutically effective amount of NK-92 cells and a therapeutically effective amount of an IL-15 agonist, wherein administration treats the merkel cell carcinoma in the subject.
    Type: Application
    Filed: June 19, 2018
    Publication date: April 23, 2020
    Applicant: NANTKWEST, INC.
    Inventors: Hans Klingemann, Tien Lee, Laurent Boissel
  • GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBOIDES FOR THE TREATMENT OF CANCER
    Publication number: 20190365816
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: August 15, 2019
    Publication date: December 5, 2019
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
    Patent number: 10456420
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 29, 2019
    Assignee: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
    Publication number: 20190300854
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Application
    Filed: May 28, 2019
    Publication date: October 3, 2019
    Applicant: NantKwest, Inc.
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
    Publication number: 20180258397
    Abstract: Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 13, 2018
    Applicant: NantKwest, Inc.
    Inventors: Hans Klingemann, Laurent Boissel, Patrick Soon-Shiong
  • GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER
    Publication number: 20180193383
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: March 25, 2016
    Publication date: July 12, 2018
    Applicant: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel